This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

For Abbott, Diversity Remains Paramount

Merck's earliest response to the FDA would be in 2010. Until that happens, Merck also won't seek FDA approval for a combination of Cordaptive and Zocor, which is now generic.

Bad news for Merck means less competition for Abbott. In February, Abbott won FDA approval for another Kos drug called Simcor, which combines Niaspan and generic Zocor. A recent Wachovia Securities report predicts the three Kos drugs could produce sales of $2.1 billion in 2012, up from an estimated $986 million this year.

Analysts are also encouraged by Abbott's follow-up to TriCor, called TriLipix, being developed with Belgium's Solvay. The FDA is due to rule on TriLipix in early October. And Abbott is collaborating with AstraZeneca (AZN) on a pill containing that company's bad-cholesterol drug Crestor and TriLipix. On Aug. 14, Abbott signed a deal to co-promote Crestor in the U.S.

Like Humira and the cholesterol drugs, Abbott got into the drug-coated stent business via an acquisition, but the 2006 deal creates concerns even for Abbott bulls.

"Uncertainty surrounding the market dynamics could pressure shares," says Rick Wise, of Leerink Swann, in a July 17 report affirming an outperform rating. However, the U.S. launch of Abbott's Xience V stent "appears to be going better than expected." The FDA approved the stent in early July.

Wise, who doesn't own shares, says Abbott predicts a 25% to 30% market share. His firm has had a recent non-investment banking relationship.

Stents are mesh-like tubes inserted into arteries that have been cleared of plaque. Stents allow blood to flow easily. Some stents are coated with a drug to prevent the artery from reclogging.
4 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ABT $36.63 -1.60%
BSX $16.60 -1.90%
GE $27.88 -1.50%
JNJ $100.14 -1.60%
MDT $72.98 -1.60%


Chart of I:DJI
DOW 15,632.24 -282.50 -1.78%
S&P 500 1,825.47 -26.39 -1.43%
NASDAQ 4,237.9050 -45.6870 -1.07%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs